Sign in

CIK 0001737287

  • Non-accelerated filer
  • Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
823562771
Phone
+1 650-457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market sale 10% owner sold 219,853 shares at an average $44.04 ($9,682,651)
  2. 4 Open-market sale 10% owner sold 314,792 shares at an average $42.50 ($13,379,623)
  3. 4 Open-market sale 10% owner sold 390,984 shares at an average $42.18 ($16,491,046)
  4. 4 Grant or award Director acquired 9,969 shares (grant or award)
  5. 4 Grant or award Director acquired 9,969 shares (grant or award)
  6. 4 Grant or award Director acquired 9,969 shares (grant or award)
  7. 4 Derivatives Options or other derivatives
  8. 4 Open-market sale 10% owner sold 489,220 shares at an average $47.40 ($23,188,152)
  9. 4 Open-market buy Director bought 146,382 shares at $47.00 ($6,879,954)
  10. 4 Other acquisition Director acquired 8,039 shares (other)
  11. 4 Gift President and CEO gave 856,044 shares (gift)
  12. 3 Insider Initial Statement of Ownership
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Grant or award Chief Technical Officer acquired 30,800 shares (grant or award)
  16. 4 Grant or award EVP of R&D and CMO acquired 30,800 shares (grant or award)
  17. 4 Grant or award Chief Financial Officer acquired 30,800 shares (grant or award)
  18. 4 Open-market sale Chief Technical Officer sold 3,750 shares at $19.19 ($71,980)
  19. 4 Open-market sale Chief Financial Officer sold 5,450 shares at an average $19.73 ($107,508)
  20. 4 Open-market sale President and CEO sold 20,335 shares at an average $19.31 ($392,615)

Page 11 of 14 · 275 filings